{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-027245","form_type":"8-K","ticker":"NXGL","cik":"0001468929","company_name":"NEXGEL, INC.","filed_at":"2025-12-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.468890+00:00","generated_at":"2026-05-16T13:29:25.928379+00:00","sec_items":["7.01","2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"NexGel spins off drug delivery program into NexGelRx; shareholders get 19.99% equity stake","bullets":["NEXGEL spins off select Rx drug delivery assets into new entity NexGelRx; retains 19.99% non-dilutive equity stake.","NEXGEL will receive a 5% global royalty in perpetuity on products sold using its drug delivery technology.","NexGelRx closed initial funding from outside investors; NEXGEL will be exclusive manufacturer of hydrogel for NexGelRx.","Dr. Jerome Zeldis, NEXGEL director who helped bring 10 pharma products to market, will also serve on NexGelRx board."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-027245","json":"https://secwatch.observer/filing/0001493152-25-027245.json","markdown":"https://secwatch.observer/filing/0001493152-25-027245.md","text":"https://secwatch.observer/filing/0001493152-25-027245.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1468929/000149315225027245/0001493152-25-027245-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1468929/000149315225027245/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:29:25.928379+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}